Pfizer's RSV vaccine enters late-stage trial, company says
Pharmaceutical company Pfizer announced on Thursday that its vaccine for the respiratory syncytial virus, or RSV, has begun the third phase of its clinical trials among adults, which comes almost two weeks after the Food Drug Administration (FDA) has fully authorized Pfizer's SARS-CoV-2 or COVID-19 vaccine.
via FOX NEWS https://ift.tt/2WRFc5l
No comments:
Post a Comment